AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04959591
Drug: intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: experimental(post): administration of IV acetaminophen
Trial: NCT04959591
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator: administration of normal saline
Trial: NCT05366764
Drug: SAR443765
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for injection
Trial: NCT05366764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for injection
Trial: NCT05994001
Drug: cardonilizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cardonilizumab:PD1 and CTLA-4 bispecific antibody
Trial: NCT05930457
Drug: 2.5-3.5mCi 64Cu-FAPI-XT117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 2.5-3.5mCi 64Cu-FAPI-XT117 injection.
Trial: NCT05930457
Drug: 4.5-5.5mCi 64Cu-FAPI-XT117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 4.5-5.5mCi 64Cu-FAPI-XT117 injection.
Trial: NCT00084032
Drug: Antiretroviral regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take any combination of FDA-approved ARV medications prescribed by their physician
Trial: NCT05988632
Drug: Regular Human Insulin then Placebo
RxNorm normalized name: insulin, regular, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin: 80 IU (administered intranasally) THEN Placebo: 0.9% saline solution (administered intranasally)
Trial: NCT05988632
Drug: Placebo then Regular Human Insulin
RxNorm normalized name: insulin, regular, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 0.9% saline solution (administered intranasally) THEN Insulin: 80 IU (administered intranasally)
Trial: NCT04565925
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Lactose) TID for 4 weeks
Trial: NCT04495751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four pills twice daily.
Trial: NCT05210374
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To be taken orally (PO) daily in the AM, rounded for pill size (max 480mg/day).~To be administered day 1-7 of lead-in week and day 1-28 cycles~Cycle length: 28 days,~maximum 12 cycles Level -1 (150mg/m\^2/day) Level~0 (225mg/m\^2/day) Level 1 (300mg/m\^2/day), max~480mg/day
Trial: NCT05210374
Drug: Liposomal Doxorubicin (Doxil)
RxNorm normalized name: doxorubicin hydrochloride liposome Injection [Doxil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To be given IV, 30mg/m2/dose~To be administered day 1 of cycles~Cycle length: 28 days, maximum 12 cycles
Trial: NCT04889287
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single doses on Day 1, Day 8, and Day 13
Trial: NCT04475835
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin is dosed at 100 U/kg. ACT is monitored 5 min after the first administration, and if the ACT \<225 s (Hemotec method), an intravenous injection of heparin should be administered by need.
Trial: NCT06010537
Drug: polysaccharide superparamagnetic iron oxide injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polysaccharide superparamagnetic iron oxide injection is a magnetic resonance contrast agent.
Trial: NCT06007066
Drug: HSK16149 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be given 40mg or 60mg of HSK16149 orally.
Trial: NCT06007066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be given HSK16149 placebo orally.
Trial: NCT04571151
Drug: LEXETTE 0.05% Topical Foam
RxNorm normalized name: LEXETTE 0.05% Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks.
Trial: NCT04571151
Drug: Sorilux 0.005 % Topical Foam
RxNorm normalized name: Sorilux 0.005 % Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application. SORILUX Foam contains calcipotriene 50 mcg/g.
Trial: NCT04614246
Drug: BAY1817080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral administration
Trial: NCT04614246
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral administration
Trial: NCT06084897
Drug: TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A maximum of six cycles was recommended for chemotherapy.~* Fluoropyrimidine (fluorouracil or capecitabine) with carboplatin or cisplatin;~* Paclitaxel (or Albumin-bound paclitaxel) with carboplatin or cisplatin.
Trial: NCT04941118
Drug: Injection of dextrose, local anesthetic and saline to the myofascial trigger point
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An injection of 5 ml of 5% dextrose prolotherapy using 2.5 ml 10% dextrose, 1 ml 2% local anesthetic (lidocaine), 1.5 ml 0.9% saline will be administered to the active group from at least 10 trigger points.
Trial: NCT04941118
Drug: Local anesthetic and saline injection to the myofascial trigger point
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 5 ml of solution created by using 4 ml of 0.9% saline and 1 ml of 2% local anesthetic (lidocaine) will be administered to the control group, with at least 10 trigger points.
Trial: NCT06585462
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered by SC or IV injection.
Trial: NCT05191017
Drug: NUV-422
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUV-422 is an investigational drug for oral dosing.
Trial: NCT04899388
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intavenous
Trial: NCT04540354
Drug: Optimal Medical Therapy (OMT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated according to Optimal Medical Therapy defined by the 2016 ESC guidelines for the management of acute and chronic heart failure.
Trial: NCT06186934
Drug: the standard-dose group (4 g/day)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with chronic kidney disease undergoing hemodialysis and controlling hyperphosphatemia
Trial: NCT06408948
Drug: [14C]SHR7280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive single dose of orally \[14C\]SHR7280 on Day 1.
Trial: NCT05471492
Drug: Investigational Product
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06480605 150 mg
Trial: NCT05471492
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06138236
Drug: Collagen hydrolyzed peptides
RxNorm normalized name: collagen, hydrolyzed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infiltration near the heal spur of 2ml of Arthrys
Trial: NCT05006768
Drug: Barcimiant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet contains 4 mg Barcitinib
Trial: NCT05488860
Drug: 5-ALA (a photosensitizer for photodynamic therapy).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For other diseases, the drug is 5-ALA (a photosensitizer for photodynamic therapy).
Trial: NCT06586606
Drug: MK-1708
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT04780269
Drug: Induction of labor with PGE2
RxNorm normalized name: Antivirals for treatment of HCV infections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE2 (1mg) will be inserted into the posterior vaginal fornix. Women will be assigned one hour of bed rest while continuously monitored by cardiotocography.
Trial: NCT06277752
Drug: dose-5 group
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI128 300mg po. QD(Quaque Die)
Trial: NCT06277752
Drug: dose-1 group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI128 25mg po. QD(Quaque Die)
Trial: NCT06277752
Drug: dose-2 group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI128 50mg po. QD(Quaque Die)
Trial: NCT06277752
Drug: dose-4 group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI128 200mg po. QD(Quaque Die)
Trial: NCT06277752
Drug: dose-3 group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI128 100mg po. QD(Quaque Die)
Trial: NCT05313997
Drug: Diclofenac Sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: at first diclofenac sodium was prescribed to patients with chronic upper back pain.~If the patient's pain persisted, she/he was included in the physical therapy (hotpack 20 minutes, ultrason 5 minutes, Transcutaneous electrical nerve stimulation 20 minutes) program.
Trial: NCT04271332
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manufactured to match Arbaclofen in size, shape, color and taste
Trial: NCT00592618
Drug: Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06632470
Drug: Secretome injection
RxNorm normalized name: gonorrheal urethral secretion human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will receive 3 ml of secretome intramuscular injection every two weeks for four months
Trial: NCT05136625
Drug: Standard Preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troncular scalp blockade. Local site infiltration
Trial: NCT06601452
Drug: a compound prescription of Chinese medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The enrolled patients were treated with 3 cycles of sequential treatment with Nourishing Yin and Replenishing Yang formula before entering the cycle (Tuning Weekly Nourishing Yin Granules + Tuning Weekly Replenishing Yang Granules), and the egg retrieval cycle used an antagonist regimen to obtain the eggs.
Trial: NCT06126991
Drug: Midazolam and Fentanyl
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam 50mg + fentanyl 300ug micro pump push will be used with a starting dose of 5ml/hour, adjusted according to the patient's level of sedation. The patient's RASS score will be maintained between -1-0 and the drug will be suspended with a blood pressure below 90/60mmHg.
Trial: NCT04702009
Drug: Anti-PD-1/PD-L1 Monoclonal Antibody，Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1/PD-L1 monoclonal antibody (approved anti-PD-1/PD-L1 monoclonal antibody)；albumin paclitaxel/docetaxel + carboplatin (albumin paclitaxel 130mg/m2, d1 d8, Docetaxel 75mg/m2, carboplatin AUC=5, d1, every 21 days, 4 cycles of chemotherapy; immunotherapy no more than 2 years)
Trial: NCT01222650
Drug: KSO-0400
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01222650
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06222944
Drug: TQB2450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450: 1200 mg, IV, D1, Q3W
Trial: NCT04221880
Drug: Saline Solution intravenously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same volume saline solution bolus and infusion as Group Lidocaine
Trial: NCT05325775
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06217120
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily
Trial: NCT04674566
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously (IV) single dose
Trial: NCT04023708
Drug: CYD-TDV Dengue Vaccine
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Solution Route of administration: Intramuscular
Trial: NCT04739709
Drug: APP13007, 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APP13007 eye drop, 0.05%
Trial: NCT04739709
Drug: Matching Vehicle Placebo for APP13007, 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching vehicle placebo eye drop
Trial: NCT04994236
Drug: Hepatic artery infusion chemotherapy with FOLFOX regimens (oxaliplatin, fluorouracil, and leucovorin)
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The FOLFOX regiments were given via hepatic artery catheterization, including oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, fluorouracil bolus 400 mg/m2, followed by fluorouracil infusion 2400 mg/m2 for 46 hours. If no severe adverse events occurred, the treatment will be repeated every 3 weeks.
Trial: NCT06142552
Drug: FRSW117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once a week, 50 weeks and as needed
Trial: NCT04821583
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone is orally administered.
Trial: NCT04821583
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is orally administered.
Trial: NCT04692688
Drug: APX3330
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APX3330, a small-molecule oral tablet, is a Ref-1 inhibitor that can potentially reduce proinflammatory and hypoxic signaling that contributes to several eye diseases.
Trial: NCT04692688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets are identical to APX3330 tablets except for the absence of the active pharmaceutical ingredient.
Trial: NCT05084404
Drug: Experimental: 4 mg/day of WY-8678 (guanabenz acetate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with nonalcoholic fatty liver disease are administered 4 mg/day of WY-8678 (guanabenz acetate) twice daily for 16 weeks
Trial: NCT05084404
Drug: Experimental: 8 mg/day of WY-8678 (guanabenz acetate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with nonalcoholic fatty liver disease are administered 8 mg/day of WY-8678 (guanabenz acetate) twice daily for 16 weeks
Trial: NCT05202145
Drug: ALXN2050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet.
Trial: NCT04914221
Drug: JLP-2002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of JLP-2002
Trial: NCT04914221
Drug: Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of comparator
Trial: NCT04709835
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose and regimen of the placebo will match that of the respective AT-527 comparator arm.
Trial: NCT05861271
Drug: Capecitabine，Pyrotinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib and Capecitabine for half a year
Trial: NCT05389696
Drug: Single subcutaneous administration and Blood collection
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous administration and Blood collection
Trial: NCT05389696
Drug: Single subcutaneous administration and then IV injection.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous administration and then single intravenous administration after 2 weeks. In addition Blood collection is conducted as scheduled.
Trial: NCT06145074
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration.
Trial: NCT06216340
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and diet-exercise therapy
Trial: NCT06169085
Drug: Leritrelvir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04711902
Drug: AIN457
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 150 mg was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection
Trial: NCT05951686
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion will be used with a dose of 0.05-2 mcg/ kg/ min under the screening with Patient State Index (PSI) between a score of 25-50 in both groups.
Trial: NCT06430060
Drug: zinc containing toothpaste
RxNorm normalized name: monofluorophosphate / potassium nitrate / zinc citrate Toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toothpaste
Trial: NCT04740970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo injection will be administered subcutaneously.
Trial: NCT06403501
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream manufactured to mimic look and feel of Clascoterone Cream 1% but without the active ingredient.
Trial: NCT05161936
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered by SC injection.
Trial: NCT05842707
Drug: dualCAR-NK19/70 cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV (vein)
Trial: NCT05721027
Drug: Ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 400 mg PO every 8 hours as needed for 7 days
Trial: NCT04837170
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
Trial: NCT04801693
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04817982
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline will be added perineurally to an ulnar nerve block with bupivacaine.
Trial: NCT05442632
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients received Placebo 5mg orally d1-14 days, surgery will be conducted at d6-14 day
Trial: NCT00009555
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05352113
Drug: SSRIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRIs antidepressants will be used and the oral dose will be determined by the clinical specialist. Once-daily for 6 weeks.
Trial: NCT05352113
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo mimicking SSRIs antidepressants. Once-daily for 6 weeks.
Trial: NCT04723069
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metronidazole tablets + doxycycline hyclate tablets, are consecutively taken for 14 days, while Fuke Qianjin capsule simulation is consecutively taken for 28 days.
Trial: NCT04723069
Drug: Test Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metronidazole tablets + doxycycline hyclate tablets simulant are consecutively taken for 14 days, while Fuke Qianjin capsule is consecutively taken for 28 days.
Trial: NCT05876312
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT05486468
Drug: Yutiq 0.18 MG Drug Implant
RxNorm normalized name: Yutiq 0.18 MG Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for intravitreal injection
Trial: NCT04093076
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered ID on Day 0 and Week 4.
Trial: NCT06466265
Drug: DNP002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CEACAM6 monoclonal antibody
Trial: NCT05593458
Drug: SOX neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cycles of SOX neoadjuvant chemotherapy every 21 days.
Trial: NCT05593458
Drug: SOX adjuvant, Sequential S-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cycles of SOX adjuvant chemotherapy every 21 days after surgery in both groups.~Sequential S-1 chemotherapy every 21 days till 1 year postoperation.
Trial: NCT05207358
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will receive Cyclophosphamide intravenously starting day 1, 6 pulses at a fixed dose of 500 mg given at 2 weeks. After 3 months, Azathioprine (2 mg / kg / day) is initiated 2 weeks after the last administration of Cyclophosphamide and maintained for the next 21 months.
Trial: NCT05207358
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 daily pulses of 750 mg of intravenous Methylprednisolone, followed by oral corticosteroid therapy starting with a dose of 0.5 mg / kg / day for 4 weeks, then decreased by 2.5 mg of Prednisolone / day each 2 weeks. A low dose of glucocorticoid (5-7.5 mg / day) is maintained until 24 months after enrollment.